The United States Pharmacopeia (USP) has announced that Dr. Gary Allmaier has been appointed director of its Research & Development Laboratory (RDL). USP’s RDL conducts analytical development and other activities in support of official USP Reference Standards. These reference standards are used to assess the strength, quality, and purity of drugs, including biologics, dietary supplements, and healthcare devices. “From aspirin to valerian and almost every drug in between, USP’s Research & Development Laboratory plays a critical role in protecting the public health by setting standards,” said Roger L. Williams, M.D., chief executive officer and executive vice president of USP. “For this reason, it is critical to have a scientist of the caliber and expertise of Dr. Allmaier at the helm. With more than 23 years of pharmaceutical experience, Dr. Allmaier can help us increase the number of reference standards available to our customers, allowing us to be an even more valuable resource.”
To date, USP’s RDL has helped support the availability of more than 1,400 official USP Reference Standards. These have been provided to more than 2,000 pharmaceutical companies in 86 countries.As the new director of RDL, Allmaier will provide leadership for the laboratory and advance its initiatives to support the development of new analytical methods for USP monographs and reference standards. Monographs are the guidelines that pharmaceutical companies use to perform specific tests, procedures, and acceptance criteria that help ensure a product’s strength, quality, and purity. Allmaier also will strengthen the lab’s role in supporting the growth of USP’s new Dietary Supplement Verification Program (DSVP).”Becoming part of the USP team is an honor,” said Gary Allmaier. “What attracted me to the position is USP’s 180-year plus reputation of protecting the public health worldwide. I am proud to be a part of this unique organization because what we do ultimately will have a direct impact on the health of individuals in the United States and around the world.”
Dr. Allmaier comes to USP from Bristol-Myers Squibb where he was responsible for managing the development of several novel drugs from discovery to new drug approval (NDA). Prior to this role, Dr. Allmaier spent 22 years in the pharmaceutical industry as an analytical research and development manager and chemist. Dr. Allmaier holds a bachelor’s in biochemistry from State University of New York at Stony Brook as well as a master’s and a doctorate in pharmaceutical sciences from Rutgers University. He is a member of Sigma Xi and Rho Chi societies. More Info – www.usp.org
